Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.
Mehmet AltanYan WangJuhee SongJames WelshChad TangNandita Guha-ThakurtaGeorge R BlumenscheinBrett W CarterJeffrey S WefelAmol J GhiaDebra N YeboaMary Frances McAleerCaroline ChungKristina D WoodhouseSusan L McGovernChenyang WangBetty Y S KimJeffrey S WeinbergTina M BriereYasir Y ElaminXiuning LeeTina CasconeMarcelo Vailati NegrãoFerdinandos SkoulidisRenata FerrarottoJohn V HeymachJing LiPublished in: Journal for immunotherapy of cancer (2023)
Concurrent brain SRS with nivolumab/ipilimumab was safe for patients with active NSCLC BM. Preliminary analyses of treatment efficacy were encouraging for intracranial treatment response.
Keyphrases
- open label
- phase iii
- phase ii
- clinical trial
- study protocol
- locally advanced
- double blind
- small cell lung cancer
- phase ii study
- placebo controlled
- optic nerve
- squamous cell carcinoma
- randomized controlled trial
- white matter
- resting state
- advanced non small cell lung cancer
- radiation therapy
- multiple sclerosis
- subarachnoid hemorrhage
- brain injury
- tyrosine kinase
- cerebral ischemia
- optical coherence tomography
- smoking cessation